IPP Bureau
NATCO receives FDA's tentative approval for Erdafitinib tablets
By IPP Bureau - February 04, 2026
NATCO’s Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alteration
Lupin launches Dasatinib tablets in US, eyes $930 million oncology market
By IPP Bureau - February 03, 2026
Artemis Medicare reports strong Q3 growth: revenue up 17%, net profit up 8%
By IPP Bureau - February 03, 2026
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
Lupin & TB Alliance team up to push groundbreaking TB drug forward
By IPP Bureau - February 03, 2026
TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide
Dr. David Berman to Join Moderna as Chief Development Officer
By IPP Bureau - February 02, 2026
Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics
Hester Biosciences posts strong Q3 profit surge as poultry business powers growth
By IPP Bureau - February 02, 2026
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY
By IPP Bureau - February 02, 2026
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
Indoco Remedies bags USFDA nod for Lacosamide oral solution
By IPP Bureau - February 02, 2026
The approved Lacosamide Oral Solution is bioequivalent and therapeutically equivalent to the reference drug and will be manufactured at Indoco’s facility in Verna Industrial Area, Goa
Dr Lal PathLabs reports Q3 revenue of Rs 660 crore, posts strong growth amid labour code impact
By IPP Bureau - February 02, 2026
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
Budget 2026-27: Government launches Rs. 10,000 crore Biopharma SHAKTI Scheme to build global manufacturing hub
By IPP Bureau - February 01, 2026
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
By IPP Bureau - February 01, 2026
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare
By IPP Bureau - February 01, 2026
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
Eli Lilly announces $3.5 billion Pennsylvania manufacturing hub
By IPP Bureau - January 31, 2026
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
AstraZeneca expands obesity and diabetes pipeline with $1.2B CSPC deal
By IPP Bureau - January 31, 2026
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
